drugset / Trial / NCT00261092
GEMOX: Oxaliplatin in Pancreatic Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary objective: * To evaluate overall response rate (based on RECIST criterion) Secondary objective: * To evaluate time to progression, clinical benefit, quality of life and safety
Timeline
- Start
- 2005-10
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | — | — |